Cognitive Impairment, MildPhase 4PREVENTABLENCT04262206
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
A Phase 4 study testing Atorvastatin 40 Mg Oral Tablet in people with Cognitive Impairment, Mild and Dementia, run by Duke University at 106 sites in 2 countries.
Trial summary
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins… Read more about this study
- Who is it for?
- Ages 75 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases
- What is being tested?
- Atorvastatin 40 Mg Oral Tablet
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20,000 participants
- Where
- 106 sitesin 2 countries
- Study dates
- 1 Sep 2020to 31 Dec 2026
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 75 years and older
- All sexes
- Healthy volunteers accepted
- Older adult
Who may be able to join
- Community-dwelling adults
- Age ≥75 years
- English or Spanish as primary language
- Able to provide a trusted contact
Who cannot join
- Clinically evident cardiovascular disease defined as prior myocardial Infarction (MI), prior stroke, prior revascularization procedure, or a secondary prevention indication for a statin (clinician determined)
- Hospitalization for a primary diagnosis of heart failure in the prior 12 months (Note: History of heart failure in the absence of recent hospitalization or clinically evident cardiovascular disease is not an exclusion)
- Dementia (clinically evident or previously diagnosed)
- Dependence in any Katz Basic Activities of Daily Living [ADL] (with the exception of urinary or bowel continence)
- Severe hearing impairment (preventing phone follow up)
- Unable to talk (preventing phone follow up)
Show all 10Show fewer
- Statin use in the past year or for longer than 5 years previously (participant reported)
- Ineligible to take atorvastatin 40 mg (clinician determined)
- Documented intolerance to statins
- Active Liver Disease
Trial locations and contacts
106 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
106 sites in 2 countries
United States104 sites, 92 recruiting
- Recruiting
VA Ann Arbor Healthcare System
Ann Arbor, Michigan, 48105
Mariam Toma, 734-883-0016, mariam.toma@va.gov
Pearl Lee
- Recruiting
University of Michigan
Ann Arbor, Michigan, 48109
Martina Nabozny, 734-385-6150, mgrenier@med.umich.edu
Pearl Lee
- Recruiting
Asheville VA-Charles George VA Medical Center
Asheville, North Carolina, 28805
Kathleen Betts, 828-298-7911 ext. 15230, kathleen.betts@va.gov
Brian Peek
- Recruiting
Atlanta VA Medical Center
Atlanta, Georgia, 30033
Mechelle Lockhart, 404-315-4100 ext. 373125, Mechelle.lockhart@va.gov
Camille Vaughan
- Recruiting
Emory University
Atlanta, Georgia, 30322
William Brown, 770-330-7790, mindandheart@emory.edu
Ambar Kulshreshtha, MD
- Recruiting
Johns Hopkins University
Baltimore, Maryland, 21287
Megan Gauvey-Kern, 443-242-4126, PREVENTABLE@jhmi.edu
Daniel Ford
- Recruiting
Bay Pines VA
Bay Pines, Florida, 33744
Anna Rosenblatt, 727-398-6661 ext. 17051, anna.rosenblatt2@va.gov
Manjunath Harlapur
- Recruiting
University of Alabama at Birmingham
Birmingham, Alabama, 35205
Destiny Taylor, 205-224-2567, destiny.taylor@uabmc.edu
Tanja Dudenbostel, MD
- Recruiting
Birmingham VA
Birmingham, Alabama, 35233
Donald Davis, 205-933-8101 ext. 334529, Donald.Davis@va.gov
Elizabeth Jackson
- Recruiting
VA Boston Healthcare System
Boston, Massachusetts, 02130
Enzo Yaksic, 617-637-5139, Enzo.Yaksic@va.gov
Ariela Orkaby
- Recruiting
University of North Carolina
Chapel Hill, North Carolina, 27599
Jeannie Ake, 919-966-9003, UNC_PREV@office.unc.edu
David Lynch
- Recruiting
Charleston VA Medical Center
Charleston, South Carolina, 29401
Alycia Blair, 843-829-2110 ext. 1011, alycia.blair@va.gov
Fernandes Jyotika
- Recruiting
Medical University of South Carolina
Charleston, South Carolina, 29403
Amy Reynolds, 843-792-8459, muscpreventable@musc.edu
Leslie Lenert
- Recruiting
Atrium Health
Charlotte, North Carolina, 28207
Kelsey Strout, 704-304-8394, preventablestudy@atriumhealth.org
Lindsay Shade
- Recruiting
Northwestern University
Chicago, Illinois, 60208
Holly Herman, 312-503-4639, holly.herman@northwestern.edu
Jeff Linder
- Recruiting
University of Illinois at Chicago
Chicago, Illinois, 60608
Naomi Ashley, 1-312-355-0083, naomiab@uic.edu
Howard Gordon
- Recruiting
Chicago VA Medical Center/Jesse Brown VA
Chicago, Illinois, 60612
Naomi Ashley, 312-569-7339, naomi.ashley@va.gov
Howard S Gordon
- Recruiting
Rush University Medical Center
Chicago, Illinois, 60612
Erin Yurko, 312-942-6596, erin_yurko@rush.edu
Raj Shah
- Recruiting
University of Chicago
Chicago, Illinois, 60637
Matt Carlson, 210-908-7749, mcarlson1@medicine.bsd.uchicago.edu
Tamar Polonsky
- Recruiting
Cincinnati VA Medical Center
Cincinnati, Ohio, 45220
Lora Morris, 513-861-3100 ext. 204417, Lora.Morris@va.gov
Jack Rubinstein
- Withdrawn
Clarksburg VA Medical Center
Clarksburg, West Virginia, 26301
- Recruiting
Case Western Reserve University
Cleveland, Ohio, 44106
Kelsey Ufholz, 216-286-2212, Kelsey.Ufholz@uhhospitals.org
Goutham Rao
- Recruiting
University of Missouri Health System
Columbia, Missouri, 65212
Vickie Grieshaber, 833-499-1938, mupreventable@health.missouri.edu
Kristin Hahn-Cover
- Recruiting
Columbia VA Health Care System/Dorn VA Medical Center
Columbia, South Carolina, 29209
Ayanna Woolridge, 803-776-4000 ext. 54083, ayanna.woolridge@va.gov
Andres Munoz
- Recruiting
Ohio State University
Columbus, Ohio, 43210
Tait Palm, 614-685-3089, preventable@osumc.edu
Seuli Brill
- Recruiting
Baylor Scott and White Medical Center
Dallas, Texas, 75210
Kionna Henderson, 214-865-3196, Kionna.Henderson@BSWHealth.org
Katherine Sanchez
- Recruiting
Dallas VA Medical Center
Dallas, Texas, 75216
Jodie-Ann Clarke, (214)857-0393, Jodie-ann.clarke@va.gov
Kyaw Soe
- Recruiting
University of Texas Southwestern Medical Center Dallas
Dallas, Texas, 75390
Gentina Thompson, 214-648-0205, gentina.thompson@utsouthwestern.edu
Craig Rubin
- Recruiting
Dayton VA Medical Center
Dayton, Ohio, 45428
Cassie Pacer, 937-268-6511 ext. 2334, cassie.pacer@va.gov
Ankur Gupta
- Recruiting
Essentia Health
Duluth, Minnesota, 55805
Leah Tatalovich, 218-576-0506, PREVENTABLE@EssentiaHealth.org
Catherine Benzinger
- Recruiting
PREVENTABLE Tele-Site
Durham, North Carolina, 27701
Khaula Baloch
Kristin Newby
- Completed
Durham VA Medical Center
Durham, North Carolina, 27705
- Recruiting
Duke University
Durham, North Carolina, 27710
Trina Phan, 919-684-9176, DukePREVENTABLE@duke.edu
Ranee Chatterjee Montgomery
- Recruiting
Mayo Clinic Health Systems - NW Wisconsin
Eau Claire, Wisconsin, 54703
Joshua Druckrey, 715-838-5831, Druckrey.Joshua@mayo.edu
Steven Rosas
- Recruiting
Doctors Hospital at Renaissance
Edinburg, Texas, 78539
Esmeralda Cardosa-Mendoza, 956-362-2391, e.cardosa@dhr-rgv.com
Juan Salazar, MD
- Recruiting
Fresno VA Medical Center
Fresno, California, 93703
Kieu Chau, 559-225-6100 ext. 4114, Kieu.chau@va.gov
Sudeshna Kundu
- Recruiting
Gainesville VA Medical Center
Gainesville, Florida, 32608
Laura Dixon, 352-548-7707, Laura.dixon1@va.gov
Sriram Peruvemba
- Recruiting
University of Florida
Gainesville, Florida, 32610
Monika Guirguis, 352-273-5919, recruit@aging.ufl.edu
Stephen Anton
- Recruiting
Hines VA Medical Center
Hines, Illinois, 60141
Holly Kramer, MD, 708-202-8387 ext. 21397, Holly.Kramer@va.gov
Holly Kramer
- Recruiting
University of Texas at Houston
Houston, Texas, 77204
Paola Robles, 713-500-7904, paola.roblescordova@uth.tmc.edu
Jessica Lee, MD
- Recruiting
Indianapolis VA Medical Center
Indianapolis, Indiana, 46202
Jared Ferguson, 317-988-9833, jared.ferguson2@va.gov
James Walsh
- Recruiting
University of Iowa Healthcare
Iowa City, Iowa, 52242
Samantha Shaffer, 319-678-7053, samantha-shaffer@uiowa.edu
Michael Ernst
- Recruiting
University of Mississippi Medical Center
Jackson, Mississippi, 39216
Lane Boyer, 601-815-8702, kboyer@umc.edu
Michael Hall
- Recruiting
VA Medical Center Jackson
Jackson, Mississippi, 39216
Anita K Spencer, 601-362-4471 ext. 51126, anita.spencer@va.gov
Anita Basu
- Recruiting
University of Florida
Jacksonville, Florida, 32608
Renae Burr, 904-244-4690, JAX-ASCENT@jax.ufl.edu
Stephen Anton
- Recruiting
Duke University - Kannapolis
Kannapolis, North Carolina, 28081
Jennifer Stiller, 704-640-7616, preventable-kannapolis@dm.duke.edu
Ranee Chatterjee
- Recruiting
University of Kansas Medical Center
Kansas City, Kansas, 66160
Erica Lower, 913-588-6052, elower@kumc.edu
Kristin Grdinovac
- Recruiting
Kansas City VA Medical Center
Kansas City, Missouri, 64128
Shamsa Kiran, 816-861-4700 ext. 56044, Shamsa.Kiran@va.gov;
Vikas Singh
- Recruiting
Mayo Clinic Health System SW Wisconsin
La Crosse, Wisconsin, 54601
Janel Tunison, 608-392-6880, tunison.janel@mayo.edu
Thomas Loepfe
- Recruiting
Little Rock VA Medical Center
Little Rock, Arkansas, 72114
Bonnie Dawson, 501-257-2523, Bonnie.Dawson2@va.gov
Kalpana Padala
- Recruiting
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72204
Patricia Savary, 501-5265701, PESavary@uams.edu
Jeanne Wei, MD
- Recruiting
Long Beach VA Medical Center
Long Beach, California, 90822
Celine Kogane, 562-826-8000 ext. 13805, celine.kogane@va.gov
Kenny Vu
- Not yet recruiting
Cedars-Sinai Medical Center
Los Angeles, California, 90048
Sandy Joung, 424-315-2284, preventable-study@cshs.org
Nicolas Musi, MD
- Recruiting
VA Greater Los Angeles
Los Angeles, California, 90073
MIkayla Guerrero, 310-478-3711 ext. 41235, mikayla.guerrero@va.gov
Cathy Lee
- Recruiting
Louisville VA Medical Center
Louisville, Kentucky, 40206
Jordan Ricks, 502-287-5208, Jordan.Ricks@va.gov
Sathya Krishnasamy
- Recruiting
Madison VA Medical Center
Madison, Wisconsin, 53705
Hannah Zylstra, 608-256-1901 ext. 17152, hannah.zylstra@va.gov
Cynthia Carlsson
- Recruiting
University of Wisconsin at Madison
Madison, Wisconsin, 53792
Hannah Zylstra, (608)262-9647, hjzylstra@medicine.wisc.edu
Cynthia Carlsson, MD
- Recruiting
Northwell Health
Manhasset, New York, 11030
Julie DiGregorio, 516-493-7950, jdigregori@northwell.edu
Joseph Conigliaro
- Recruiting
Marshfield Clinic
Marshfield, Wisconsin, 54449
Diane Kohnhorst, 888-367-4413, PREVENTABLE@marshfieldresearch.org
Jeffrey Vanwormer
- Recruiting
VA Northern California Health Care System
Mather, California, 95655
Maria Spinelli, 925-895-5196, maria.spinelli@va.gov
Ajay Sood
- Completed
VA Medical Center Memphis
Memphis, Tennessee, 38104
- Completed
Miami VA Medical Center
Miami, Florida, 33125
- Recruiting
University of Miami
Miami, Florida, 33136
Yesenia Levi, 786-877-7710, yxl878@miami.edu
Olveen Carrasquillo
- Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin, 53295
Madeline Berendt, 414-805-7291, PREVENTABLE@mcw.edu
Jake Decker
- Recruiting
Milwaukee VA Medical Center
Milwaukee, Wisconsin, 53295
Julie Lorscheter, 414-384-2000 ext. 46627, julie.lorscheter@va.gov
Jeffrey Whittle
- Active, not recruiting
Allina Health
Minneapolis, Minnesota, 55407
- Withdrawn
Minneapolis VA Health Care System
Minneapolis, Minnesota, 55417
- Withdrawn
VA Hudson Valley Healthcare System
Montrose, New York, 10548
- Recruiting
Intermountain
Murray, Utah, 84107
Tyler Winslow, 801-507-4565, preventablestudy@imail.org
Kirk Knowlton
- Recruiting
Meharry Medical College
Nashville, Tennessee, 37208
Steven Houtschilt, 615-398-2741, shoutschilt@mmc.edu
Richmond Akatue
- Recruiting
Nashville VA Medical Center
Nashville, Tennessee, 37212
Jennifer Wharton, 615-873-6055, Jennifer.Wharton@va.gov
Christianne Roumie
- Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee, 37212
Jennifer Wharton, 615-322-6191, jennifer.wharton@vumc.org
Amanda Mixon
- Recruiting
Yale University
New Haven, Connecticut, 06520
Meilyn Madrigal, 203-737-2252, meilyn.madrigal@yale.edu
Thomas Gill
- Completed
University Medical Center
New Orleans, Louisiana, 70112
- Recruiting
Ochsner Clinic Foundation
New Orleans, Louisiana, 70121
Shannon Williams, 504-842-6487, slwilliams@ochsner.org
Lydia Bazzano
- Recruiting
VA New York Harbor Healthcare System
New York, New York, 10010
Natalie Nejaime, 212-951-3395, natalie.nejaime@va.gov
Sundar Natarajan
- Recruiting
Weill Cornell Medical College
New York, New York, 10021
Fernando Park, 607-204-9070, preventable@med.cornell.edu
Parag Goyal
- Recruiting
North Chicago VA Medical Center
North Chicago, Illinois, 60064
Erica Noel, 224-610-7140, erica.noel@va.gov
Raul J Gazmuri
- Recruiting
University of Nebraska Medical Center
Omaha, Nebraska, 67105
Amy Peterson, 1-402-552-7737, preventable@unmc.edu
Alfred Fisher
- Recruiting
Omaha VA Medical Center
Omaha, Nebraska, 68105
Ari Bader, 402-552-7737, ari.bader@va.gov
Alfred Fisher
- Withdrawn
VA Palo Alto Healthcare System
Palo Alto, California, 94550
- Withdrawn
Corporal Michael J. Crescenz VA Medical Center-Philadelphia VA
Philadelphia, Pennsylvania, 19104
- Not yet recruiting
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107
William Leach, 636-253-7191, William.Leach@jefferson.edu
Christopher Chambers
- Recruiting
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213
Emily Klawson, 412-586-9796, klawson2@upmc.edu
Daniel Forman
- Not yet recruiting
Oregon Health and Science University
Portland, Oregon, 97239
Matthew Howard, 503-494-1583, howamat@ohsu.edu
Elizabeth Eckstrom
- Recruiting
Providence VA Medical Center
Providence, Rhode Island, 002908
Sarah Richer, 401-273-7100 ext. 16465, sarah.richter@va.gov
Gaurav Choudhary
- Withdrawn
Reno VA/Sierra Nevada Health Care
Reno, Nevada, 89502
- Recruiting
McGuire VA Medical Center
Richmond, Virginia, 23219
Charmaine Taylor, 804-675-5000 ext. 17301, charmaine.taylor@va.gov
Michael Godschalk
- Recruiting
Mayo Clinic
Rochester, Minnesota, 55905
Angela Meilander, 507-293-9539, RSTPREVENTSTUDY@mayo.edu
Alanna Chamberlain
- Active, not recruiting
University of Utah
Salt Lake City, Utah, 84132
- Recruiting
VA Salt Lake City Healthcare System
Salt Lake City, Utah, 84148
Cosette Pryor, 385-580-3966, cosette.pryor@va.gov
Amy Cowan
- Recruiting
San Antonio VA Medical Center
San Antonio, Texas, 78229
Kristy Michalek, 210-617-5900 ext. 116210, kristy.michalek@va.gov
Marcos Restrepo
- Recruiting
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78229
Kevin Brown, 210-450-3045, Brownk5@uthscsa.edu
Nicolas Musi
- Recruiting
VA San Diego Medical Center
San Diego, California, 92161
Melissa St. John, 858-642-1129, Melissa.St.John@va.gov
William Penny
- Recruiting
St. Louis VA Medical Center
St Louis, Missouri, 63106
Maureen Dempsey, 314-750-1591, maureen.dempsey@va.gov
Jaifu Ou
- Recruiting
Washington University in St. Louis
St Louis, Missouri, 63130
Amy Young, 314-273-0338, amyyoung@wustl.edu
Ellen Binder, MD
- Recruiting
Albert Einstein College of Medicine
The Bronx, New York, 10461
Yessica E Vanterpool, 718-430-3422, yessica.estrellavanterpool@einsteinmed.edu
Carlos Rodriguez
- Recruiting
Bronx VA Medical Center
The Bronx, New York, 10468
Raynier Baez, 718-584-9000 ext. 6099, raynier.baezguerrero@va.gov
Matthew Augustine
- Recruiting
Maine VA Health Care System
Togus, Maine, 04330
Houlton Boomer, 207-623-8411 ext. 2592, houlton.boomer@va.gov
David Duchin
- Recruiting
VA Eastern Kansas Healthcare System
Topeka, Kansas, 66622
Karen Reuben-Hallock, 913-682-2000 ext. 64167, Karen.Reuben-Hallock@va.gov
Alexander Hallock
- Recruiting
Southern Arizona VA Health Care System - Tucson
Tucson, Arizona, 85723
Sarah Miranda, (520)792-1450 ext. 15245, sarah.miranda1@va.gov
Ann Marie Canelas
- Recruiting
VA Connecticut Healthcare System
West Haven, Connecticut, 006111
Study Coordinator, 203-932-5711 ext. 2842
Brian Malm
- Recruiting
Wake Forest Baptist Hospital-Cardiology
Winston-Salem, North Carolina, 27157
Sophia Dawson, 336-713-2338, sadawson@wakehealth.edu
Michael Shapiro
- Recruiting
Wake Forest Hospital - Geriatrics
Winston-Salem, North Carolina, 27157
Jesus Betancourt, 336-713-8659, jbetanco@wakehealth.edu
Ezequiel Zamora
Puerto Rico2 sites, 2 recruiting
- Recruiting
VA Caribbean Healthcare System
San Juan, Puerto Rico, 00921
William Rodriguez-Cintron, MD, 787-641-7582 ext. 110116, william.rodriguez@va.gov
William Rodriguez-Cintron
- Recruiting
VA Carribbean Healthcare
San Juan, Puerto Rico, 00921
William Rodriguez-Cintron, MD, 787-641-7582 ext. 110116, williams.rodriguez@va.gov
William Rodriguez-Cintron
About this study
Official title: PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.
Read the detailed description
PREVENTABLE will randomly assign atorvastatin 40 mg daily or matching placebo daily to approximately 20,000 community-dwelling adults 75 years of age or older without clinically evident cardiovascular disease, significant disability, or dementia, and follow them for up to 5 years (estimated median of 3.8 years). The study will enroll participants from approximately 100 US sites. Community engagement efforts will leverage community groups and practices as collaborators for recruitment. We plan to partner with participants, caregivers, and clinicians in all aspects of the study. The enrolling sites are non-VA and VA sites. To assist in recruitment, sites will apply a study-specific cohort identification algorithm to their electronic health record to create a list of eligible participants based on study inclusion and exclusion criteria. The cohort identification will exclude individuals with clinically evident cardiovascular disease, significant disability, or dementia and other exclusions obtainable from data queries to define a potential cohort. Additionally, the PREVENTABLE CCC will provide a centralized support team to assist with recruitment and retention efforts. This includes mass mailings and/or phone calls to potential participants and a toll-free number for potential participants to call for information and pre-screening. Interested and potentially eligible participants will be referred to an enrolling site near them, if applicable, otherwise, they will be referred to the PREVENTABLE Telesite which is capable of enrolling English and Spanish-speaking participants across the U.S. remotely. Sites will screen potential participants to confirm eligibility and consent and randomize those interested in joining the study. Specifically related to dementia, the qualifying exclusion is a clinical diagnosis in the chart or clinician's assessment that dementia may be present.
Sites will enter contact information, mailing address for study drug, demographic information, height, weight, statin history (if any), Social Security Number, and aspects of the medical history not obtainable from EHR. In addition, a Short Physical Performance Battery (SPPB) and Activities of Daily Living (ADL) screen will be site-performed at baseline. SPPB will provide an objective assessment of function for understanding frailty and physical function of the enrolled population. Baseline lipid panel (core lab) and biospecimen samples will be obtained using the same blood draw for 20cc of blood. Blinded lipid testing will be performed at baseline on all participants (n=20,000) and repeated at 3 months in a random subset (n=2,000). Lipid panels will be sent to the PREVENTABLE Core Lab to maintain study blind. Future testing of lipid panels during routine clinical care will be actively discouraged, but other laboratory testing as indicated by clinical care is permitted. Sites will have the option for telehealth enrollment. Baseline SPPB and Biorepository Labs are not required, but encouraged.
As part of the study operations, with the rationale of providing patient centricity, ease of participation, and access for vulnerable and at risk participants, follow up will be performed by a central call center. The baseline and annual assessments performed centrally will include a phone screen for cognitive function (TICS-M) and physical function (Patient-reported Outcome Measurement Information System-Physical Function [PROMIS-PF]). After year 1, if baseline calls indicated by crossing pre-specified cutpoints, in-person assessments will be completed by trained and certified research staff at a mutually agreed upon time and a standardized interview of a knowledgeable informant. Cardiovascular event ascertainment will be via a systematic approach to data curation from the EHR, Medicare, and National Death Index. For convenience and compliance, the study pharmacy will mail a supply of study drug, sufficient for 90 days, directly to participants. This will start immediately after randomization and continue as long as the participant is on study drug.
- Being tested
- Atorvastatin 40 Mg Oral Tablet, Placebo oral tablet
- Keywords
- statin, older adults
- Medical subject headings
- Cognitive Dysfunction, Dementia, Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Atorvastatin 40 Mg Oral TabletDrug
Also called Lipitor
To generate knowledge about the role of statins in older adults in whom risk/benefit for primary prevention is understudied,
Placebo oral tabletDrug
To generate knowledge about the role of statins in older adults in whom risk/benefit for primary prevention is understudied,
| Study group | Role | What they receive |
|---|---|---|
| atorvastatin 40mg | Experimental | 40mg atorvastatin po qd from consent to study end Receives: Drug: Atorvastatin 40 Mg Oral Tablet |
| Placebo | Placebo comparator | matching placebo po qd from consent to study end Receives: Drug: Placebo oral tablet |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of patients without diagnosis of new dementia
Number of patients without diagnosis of new dementia in each group (placebo vs. atorvastatin)
Measured: 4 years
Number of patients without of persistent disability
Number of patients without chronic disability in each group
Measured: 4 years
Secondary outcomes (2)
Cardiovascular mortality measured as a composite of CV death, hospitalization for myocardial infarction/unstable angina, heart failure, stroke/TIA, or coronary revascularization
Cardiovascular mortality is measured by a composite measure of multiple CV conditions.
Measured: 4 years
Cognitive disability as measured as a composite of MCI or probable dementia
Cognitive disability is measured by a composite of having mild cognitive impairment or probable dementia.
Measured: 4 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Feb 2020
- Study start1 Sep 2020
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Cognitive Impairment, MildStudies of the same condition, open and under way.
- More trials run by Duke UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized 1:1 atorvastatin 40mg vs. placebo
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 20,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Duke University
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Aging (NIA), National Heart, Lung, and Blood Institute (NHLBI), Wake Forest University Health Sciences
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04262206
- Sponsor's protocol ID
- Pro00103844
- Other IDs
- 1U19AG065188-01
- Acronym
- PREVENTABLE
- Status last verified
- Jun 2026
- First submitted
- 7 Feb 2020
- Last updated
- 1 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Speiser JL, Ambrosius WT, Pajewski NM. Performance of Cox regression models for composite time-to-event endpoints with component-wise censoring in randomized trials. Clin Trials. 2023 Oct;20(5):507-516. doi: 10.1177/17407745231177046. Epub 2023 May 26.
PubMed 37243355Joseph J, Pajewski NM, Dolor RJ, Sellers MA, Perdue LH, Peeples SR, Henrie AM, Woolard N, Jones WS, Benziger CP, Orkaby AR, Mixon AS, VanWormer JJ, Shapiro MD, Kistler CE, Polonsky TS, Chatterjee R, Chamberlain AM, Forman DE, Knowlton KU, Gill TM, Newby LK, Hammill BG, Cicek MS, Williams NA, Decker JE, Ou J, Rubinstein J, Choudhary G, Gazmuri RJ, Schmader KE, Roumie CL, Vaughan CP, Effron MB, Cooper-DeHoff RM, Supiano MA, Shah RC, Whittle JC, Hernandez AF, Ambrosius WT, Williamson JD, Alexander KP; PREVENTABLE Trial Research Group. Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale. J Am Geriatr Soc. 2023 Jun;71(6):1701-1713. doi: 10.1111/jgs.18312. Epub 2023 Apr 20.
PubMed 37082807Rozing MP, Westendorp RGJ. Altered cardiovascular risk pattern of LDL cholesterol in older adults. Curr Opin Lipidol. 2023 Feb 1;34(1):22-26. doi: 10.1097/MOL.0000000000000859. Epub 2022 Nov 16.
PubMed 36413436
Study at a glance
From the registry record, last updated by the sponsor on 1 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)
- ClinicalTrials.gov ID
- NCT04262206
- Acronym / sponsor ID
- PREVENTABLE / Pro00103844
- Keywords
- statin, older adults
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 20,000 participants (estimated)
- Lead sponsor
- Duke UniversityUniversity, hospital or other
- Collaborators
- National Institute on Aging (NIA), National Heart, Lung, and Blood Institute (NHLBI), Wake Forest University Health Sciences
- Study start
- 1 Sep 2020 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 10 Feb 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.
Detailed description
PREVENTABLE will randomly assign atorvastatin 40 mg daily or matching placebo daily to approximately 20,000 community-dwelling adults 75 years of age or older without clinically evident cardiovascular disease, significant disability, or dementia, and follow them for up to 5 years (estimated median of 3.8 years). The study will enroll participants from approximately 100 US sites. Community engagement efforts will leverage community groups and practices as collaborators for recruitment. We plan to partner with participants, caregivers, and clinicians in all aspects of the study. The enrolling sites are non-VA and VA sites. To assist in recruitment, sites will apply a study-specific cohort identification algorithm to their electronic health record to create a list of eligible participants based on study inclusion and exclusion criteria. The cohort identification will exclude individuals with clinically evident cardiovascular disease, significant disability, or dementia and other exclusions obtainable from data queries to define a potential cohort. Additionally, the PREVENTABLE CCC will provide a centralized support team to assist with recruitment and retention efforts. This includes mass mailings and/or phone calls to potential participants and a toll-free number for potential participants to call for information and pre-screening. Interested and potentially eligible participants will be referred to an enrolling site near them, if applicable, otherwise, they will be referred to the PREVENTABLE Telesite which is capable of enrolling English and Spanish-speaking participants across the U.S. remotely. Sites will screen potential participants to confirm eligibility and consent and randomize those interested in joining the study. Specifically related to dementia, the qualifying exclusion is a clinical diagnosis in the chart or clinician's assessment that dementia may be present.
Sites will enter contact information, mailing address for study drug, demographic information, height, weight, statin history (if any), Social Security Number, and aspects of the medical history not obtainable from EHR. In addition, a Short Physical Performance Battery (SPPB) and Activities of Daily Living (ADL) screen will be site-performed at baseline. SPPB will provide an objective assessment of function for understanding frailty and physical function of the enrolled population. Baseline lipid panel (core lab) and biospecimen samples will be obtained using the same blood draw for 20cc of blood. Blinded lipid testing will be performed at baseline on all participants (n=20,000) and repeated at 3 months in a random subset (n=2,000). Lipid panels will be sent to the PREVENTABLE Core Lab to maintain study blind. Future testing of lipid panels during routine clinical care will be actively discouraged, but other laboratory testing as indicated by clinical care is permitted. Sites will have the option for telehealth enrollment. Baseline SPPB and Biorepository Labs are not required, but encouraged.
As part of the study operations, with the rationale of providing patient centricity, ease of participation, and access for vulnerable and at risk participants, follow up will be performed by a central call center. The baseline and annual assessments performed centrally will include a phone screen for cognitive function (TICS-M) and physical function (Patient-reported Outcome Measurement Information System-Physical Function [PROMIS-PF]). After year 1, if baseline calls indicated by crossing pre-specified cutpoints, in-person assessments will be completed by trained and certified research staff at a mutually agreed upon time and a standardized interview of a knowledgeable informant. Cardiovascular event ascertainment will be via a systematic approach to data curation from the EHR, Medicare, and National Death Index. For convenience and compliance, the study pharmacy will mail a supply of study drug, sufficient for 90 days, directly to participants. This will start immediately after randomization and continue as long as the participant is on study drug.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
- Model description
- Randomized 1:1 atorvastatin 40mg vs. placebo
| Arm | Type | Receives |
|---|---|---|
| atorvastatin 40mg | Experimental | Drug: Atorvastatin 40 Mg Oral Tablet40mg atorvastatin po qd from consent to study end |
| Placebo | Placebo comparator | Drug: Placebo oral tabletmatching placebo po qd from consent to study end |
Who may qualify
- Ages
- 75 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Older adult
Key inclusion criteria (4 listed)
- Community-dwelling adults
- Age ≥75 years
- English or Spanish as primary language
- Able to provide a trusted contact
Key exclusion criteria (10 listed)
- Clinically evident cardiovascular disease defined as prior myocardial Infarction (MI), prior stroke, prior revascularization procedure, or a secondary prevention indication for a statin (clinician determined)
- Hospitalization for a primary diagnosis of heart failure in the prior 12 months (Note: History of heart failure in the absence of recent hospitalization or clinically evident cardiovascular disease is not an exclusion)
- Dementia (clinically evident or previously diagnosed)
- Dependence in any Katz Basic Activities of Daily Living [ADL] (with the exception of urinary or bowel continence)
- Severe hearing impairment (preventing phone follow up)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Atorvastatin 40 Mg Oral TabletAlso: LipitorTo generate knowledge about the role of statins in older adults in whom risk/benefit for primary prevention is understudied, | Drug | atorvastatin 40mg |
| Placebo oral tabletTo generate knowledge about the role of statins in older adults in whom risk/benefit for primary prevention is understudied, | Drug | Placebo |
Primary outcome
Number of patients without diagnosis of new dementia
Time frame: 4 years
Number of patients without diagnosis of new dementia in each group (placebo vs. atorvastatin)
Number of patients without of persistent disability
Time frame: 4 years
Number of patients without chronic disability in each group
2 secondary outcomes
Cardiovascular mortality measured as a composite of CV death, hospitalization for myocardial infarction/unstable angina, heart failure, stroke/TIA, or coronary revascularization
Time frame: 4 years
Cognitive disability as measured as a composite of MCI or probable dementia
Time frame: 4 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Sep 2026.
- Derived from this study: PubMed 37243355Speiser JL, Ambrosius WT, Pajewski NM. Performance of Cox regression models for composite time-to-event endpoints with component-wise censoring in randomized trials. Clin Trials. 2023 Oct;20(5):507-516. doi: 10.1177/17407745231177046. Epub 2023 May 26.
- Derived from this study: PubMed 37082807Joseph J, Pajewski NM, Dolor RJ, Sellers MA, Perdue LH, Peeples SR, Henrie AM, Woolard N, Jones WS, Benziger CP, Orkaby AR, Mixon AS, VanWormer JJ, Shapiro MD, Kistler CE, Polonsky TS, Chatterjee R, Chamberlain AM, Forman DE, Knowlton KU, Gill TM, Newby LK, Hammill BG, Cicek MS, Williams NA, Decker JE, Ou J, Rubinstein J, Choudhary G, Gazmuri RJ, Schmader KE, Roumie CL, Vaughan CP, Effron MB, Cooper-DeHoff RM, Supiano MA, Shah RC, Whittle JC, Hernandez AF, Ambrosius WT, Williamson JD, Alexander KP; PREVENTABLE Trial Research Group. Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale. J Am Geriatr Soc. 2023 Jun;71(6):1701-1713. doi: 10.1111/jgs.18312. Epub 2023 Apr 20.
- Derived from this study: PubMed 36413436Rozing MP, Westendorp RGJ. Altered cardiovascular risk pattern of LDL cholesterol in older adults. Curr Opin Lipidol. 2023 Feb 1;34(1):22-26. doi: 10.1097/MOL.0000000000000859. Epub 2022 Nov 16.
- Individual participant dataSharing planned: No
Related trials for Cognitive Impairment, Mild
RecruitingPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Alzheimer s Disease, Mild Cognitive Impairment
RecruitingObservational study
Community-based Screening for Alzheimer's Disease
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
RecruitingObservational study
InRAD Observational Study
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
Recruiting
Treating Insomnia in Mild Cognitive Impairment
Mild Cognitive Impairment (MCI), Insomnia
Recruiting
Telehealth-Adapted Compensatory Training and Intervention for Cognition
MCI, Mild Cognitive Impairment
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
106 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Atorvastatin 40 Mg Oral Tablet in people with Cognitive Impairment, Mild and Dementia, run by Duke University at 106 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 1 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 106 sites in United States, Puerto Rico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Pamela Monds (9196688695, pamela.monds@duke.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of patients without diagnosis of new dementia (time frame: 4 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04262206, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Sep 2026.